News | March 05, 2008

Combining PET, CT Beneficial for Some Cancer Patients

March 5, 2008 – Combining PET and CT for radiation therapy treatment planning in head and neck carcinoma patients provides local and regional disease control in comparison to CT alone, said a study in the March 1 issue of the International Journal for Radiation Oncology Biology Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

This study was conducted to calculate the clinical outcomes, including overall survival, disease-free survival and the incidence of recurrence of patients receiving PET/CT-guided radiation therapy and the correlation of the clinical outcomes to the maximum standard uptake value obtained on the PET scan.

According to the study, between Dec. 2002 and Aug. 2006, 42 patients with a median age of 55, who were diagnosed with head and neck squamous cell carcinoma, were given PET/CT imaging as part of their radiation therapy planning. The patients were monitored for at least six months following their treatment, with a mean follow-up time of 32 months.

Overall survival of the 42 study patients was 82.8 percent at two years and 74.1 percent at three years, superior to the survival rate that was found in a Radiation Therapy Oncology Group study in which patients received standard fractionation or accelerated fractionation with concomitant boost, said the study.

Results found that disease free survival for the 42 study patients was 71 percent and 66.9 percent at two and three years respectively. The cumulative incidence of recurrence was 18.7 percent. The study also found that standard uptake value quality predictor of local recurrence and that dose escalation based on standard uptake value is unlikely to be a fruitful treatment strategy, said the organization.

CT has been the go to decision for treatment planning for head and neck squamous cell carcinomas, but PET is proven to have an advantage over CT and other imaging modalities for primary tumor detection, including involved lymph nodes and distant metastatic disease not clearly otherwise identified. Using solely PET does have several disadvantages though, such as poor correlation to precise anatomic structures, but these negative impacts are reduced when PET and CT are combined by fusing the separate scans taken on a hybrid scanner.

For more information: www.astro.org

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init